Fig. 1: FLT3ITD in molecularly defined AML subgroups and prognostic impact of co-occurring DNMT3A, TET2, ASXL1 (DTA) mutations in NPM1MUT/ FLT3ITD AML. | Blood Cancer Journal

Fig. 1: FLT3ITD in molecularly defined AML subgroups and prognostic impact of co-occurring DNMT3A, TET2, ASXL1 (DTA) mutations in NPM1MUT/ FLT3ITD AML.

From: Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data

Fig. 1: FLT3ITD in molecularly defined AML subgroups and prognostic impact of co-occurring DNMT3A, TET2, ASXL1 (DTA) mutations in NPM1MUT/ FLT3ITD AML.The alternative text for this image may have been generated using AI.

A Multivariable Cox regression forest plot evaluating the effect of FLT3ITD on overall survival (OS) across molecularly defined AML subgroups. Models were adjusted for age, sex, FLT3 inhibitor use, and HSCT. B Kaplan–Meier curves of OS in NPM1MUT/ FLT3ITD AML according to DTA co-mutation status, compared with ELN 2022 adverse-risk AML. C Event-free survival in NPM1MUT/ FLT3ITD AML stratified by DTA co-mutation status, with comparison to the ELN 2022 adverse-risk group. D Relapse-free survival in NPM1MUT/ FLT3ITD AML according to DTA co-mutation status and ELN 2022 adverse-risk classification. TF transcription factor, HSCT hematopoietic stem cell transplantation.

Back to article page